Introduction

More than 30 years ago, partial splenic embolization (PSE) started being used for two frequent consequences of increased portal vein pressure: esophageal variceal hemorrhage and platelet sequestration in spleen [1]. Even though it revealed its value, it took a while for splenic embolization to get more accepted due to an elevated rate of adverse events, mainly spleen abscess formation, sepsis, spleen disruption, pancreas inflammation due to nontarget embolization and severe pulmonary infection [2]. Recent literature, however, has demonstrated significant reduction in complication and mortality rates resulting from various reasons including improvements in the available materials for transcatheter embolization and angiography equipment, added to the changes in the PSE procedure, learned throughout the past 20 years [3–6].
Currently, interventional radiology approach to the splenic artery is used to handle a myriad of diseases, such as splenic contusion, platelets sequestration, splenic artery aneurysmal formations, increased portal vein pressure, and tumors of the spleen [2]. It is also indicated in the management of reduced splenic artery flow, increasing blood irrigation to livers after hepatic transplantation and improving platelet counts in patients with thrombocytopenia in the course of anti-cancer treatment or suppressive therapy in hepatitis C [3].

A decrease in hematological parameters, mainly platelets count drop, derived from splenic sequestration can appear in numerous medical conditions, frequently resultant of increased portal vein pressure and augmentation of spleen in patients with cirrhosis or those who present with disturbances of the main portal vein and its tributaries [7, 8]. The reduction in the platelets count in the hypersplenism clinical picture is largely triggered through augmented splenic retention or thrombocytes damage, even though other implicated issues have been described such as thrombopoietin degradation by platelets retained inside the spleen. Reduction in the production of thrombopoietin in cases of extensive liver metastasis or advanced hepatic cirrhosis might likewise induce thrombocytopenia [9].

Systemic chemotherapy (SC), principally those based in oxaliplatin administration, induced liver toxicity and damage can provoke a medical state equivalent to hypersplenism present in patients with hepatic cirrhosis [10]. Analysis of the normal liver after major hepatectomies in patients with colon and rectal cancer have already demonstrated distinguished toxic consequences on liver parenchyma derived from SC administration. When spleen enlargement and platelets sequestration develop in the course of the SC treatment, the consequential low platelets count can interrupt patient regimen or force dosage reduction, decreasing the efficiency of cancer therapy [11]. Prescription attenuation or chemotherapy suspension is imposed when thrombocytopenia reaches 75 × 10^9/L throughout cancer regimens administration. Chemotherapy-induced thrombocytopenia (CIT) has been previously defined as an amount fewer than 75 × 10^9/L that produces an inappropriate anti-cancer therapeutic effect [12, 13].

### Methods

We formulated a prospective, phase II, single-arm and single-center study for the evaluation of PSE in patients with CIT that impeded SC continuation. From August 2014 through July 2015, 33 patients underwent PSE in order to increase platelets count to allow their return to SC. Spleen sequestration was the supposed origin of the CIT in our patients supported by medical history evaluation and laboratory and radiological appraisal [10, 14]. Our primary endpoint of interest was the accomplishment of a thrombocyte level superior to 130 × 10^9/L and the secondary endpoints were the return to SC and the occurrence of adverse events. PSE was performed if the patient presented thrombocytopenia of 75 × 10^9/L or less and after a consensus decision between the Clinical Oncology Department and the Interventional Radiology Team. Platelets counts were recorded prior to and 1, 2, 3, and 4 weeks after PSE. Pre- and post procedure computed tomography (CT) imaging was performed in all patients for the evaluation of splenic augmentation and infarction area. Before PSE, splenic dimensions were recorded in a single measurement fashion since it correlates well with total volume of the spleen and the finding of splenomegaly [11]. To estimate necrosis, the same measurement routine was done, in the one to 2 week post-PSE CT, taking into account the infarcted area and the preserved parenchyma. If a single measurement was not possible at the post-PSE CT, because of its necrotic pattern appearance, a subjective analysis of the infarcted splenic parenchyma amount was done in agreement by two radiologists. Laboratory values were recorded before, during, and after the embolization procedures. Length of hospital permanence, SC regimen used prior to PSE, length of SC interruption, and the occurrence of adverse events were additionally recorded. CT of the superior abdomen was done 1 week after PSE and compared to the final post PSE angiography to evaluate splenic infarcted area accordance level. We opted not to give vaccinations since with partial splenic embolization patient’s spleen immune protection would not be completely eliminated.

### PSE technique

PSE’s were executed by one interventional radiology fellow and one staff member. Patients were sedated with intravenous medications. Dedicated pre, per, and post angiography was done to identify left gastroepiploic artery, short gastric branches and pancreatic body and tail branches in order to avoid unintended embolization [15]. Following microcatheterization of branches supplying the splenic lower pole, embolization was executed with 1 vial of 100–300 microspheres (Bead Block® Terumo) mixed with 80 mg of gentamycin. We preferentially occluded splenic artery lower pole branches in order to minimize the occurrence of pleural effusion or subdiaphragmatic abscess [16]. The superselective catheterization and the use of microspheres aims to achieve a more predictable embolized area as possible. Additional embolic material was used at the Interventional Radiologist discretion and endpoint was stasis for all procedures. For the embolized splenic parenchyma estimation, a final arteriogram was routinely performed. The embolization target for this study was to attain at least 50% of infarcted spleen tissue and to not go beyond 70% (Fig. 1).
and this goal was estimated by the performing interventional radiologist at the end of every procedure. Subsequently, this endpoint analysis was confronted with the opinion of other interventional radiologist for agreement and in the case of divergence, a mean value was adopted. All patients received intravenous analgesia with 2 g of Dipirona during PSE and intravenous morphine (Dimorph®) at the operator depiction. Patients’ immediate recuperation after PSE occurred in our interventional radiology beds for half dozen hours. We attempted, whenever possible, same-day hospital discharged, but symptomatic patients were kept overnight for intravenous analgesia and antiemetic medications. All patients were oriented to take oral pain medication for 5 days and antibiotics for 7 days after PSE.

Statistical analysis

Summary statistics were calculated for platelet count as well as other demographic and clinical characteristics of interest. Percent of patients achieving primary endpoint by week was calculated. The association of the binary primary endpoint of interest (thrombocyte level superior to $130 \times 10^9$/L, yes/no) with clinical factors of interest was tested using logistic regression models. Additionally, the association between observed thrombocyte count at week 2 and clinical factors was tested using linear regression models. The clinical factors of interest included number of cycles, estimated fraction of spleen necrosis by angiography, estimated fraction of spleen necrosis by CT, type of material and size of particle. The correlation of spleen necrosis fraction by angiography with spleen necrosis fraction by CT was also tested using linear regression.

Ethics approval, conflicts of interest, and funding

The ethics committee of the Brazilian’s National Cancer Institute (INCA) approved the study protocol (Approval #31770814.7.000.5274). All patients provided written informed consent. There was no funding for this work. The authors declare no conflicts of interest.

Results

PSE was done 36 times in 33 patients, 13 men and 20 women. The youngest patient was 32 years old and the oldest one 83 years old (mean age 58.8 years, median 59 years) and performance status ranged from 0 to 1. Gastrointestinal cancer was present in the absolute majority of the patients and colorectal cancer ($n = 29$ patients) was the most common primary site. Twenty patients presented hepatic metastases, while metastases were also present in the lung and peritoneum in 11 and four patients, respectively. An average of 6.4 cycles of SC was done before PSE and the most common chemotherapy regimen was Folfox, used in 24 patients (71%). Five patients received Xeloda (15%), two patients received Folfiri (6%), one patient received Folfirinox (3%), one patient received Sorafenib (3%), and one patient received 5FU alone (3%). Overall, 29 patients (88%) received some form of oxaliplatin-based SC regimen. Two patients had hepatitis C and cirrhosis and one patient also had lymphoma.

All patients were submitted to PSE only once except for two patients: in one, PSE was performed twice and in another, it was performed three times due to subsequent declines in platelets count after SC was reinitiated. Mean platelet count prior to PSE was $69 \times 10^9$/L, median of $71 \times 10^9$/L, interquartile range $62–76 \times 10^9$/L, maximum platelet count was $94 \times 10^9$/L confirming low platelet count for all patients prior to PSE. Overall, 94% of patients achieved our primary endpoint. By week, the percent of patients achieving the primary endpoint was 39%, 86%, 63%, and 46% in weeks 1, 2, 3, and 4, respectively. Mean platelet count at weeks 1, 2, 3, and 4 post-PSE were $141 \times 10^9$/L (range $61–273 \times 10^9$/L), $188 \times 10^9$/L (range $92–378 \times 10^9$/L), $154 \times 10^9$/L (range $38–302 \times 10^9$/L),

Figure 1. (A) Computed tomography showing enlarged spleen in a patient with colorectal cancer after 7 cycles of Folfox. (B) Pre-embolization arteriogram showing usual splenic arterial anatomy. (C) Immediate post partial splenic embolization (PSE) arteriogram showing embolization of approximately 50% of the splenic parenchyma (D) Computed tomography 2 weeks after PSE showing partial spleen necrosis, which accurately correlated with the post PSE arteriogram.
122 × 10⁹/L (range 8–234 × 10⁹/L), respectively. All patients in need (31 patients) were able to reinitiate treatment, and the median time to return to SC was 14 days (mean 17.7 days). Platelets count new decrease, starting at the third week, was accompanied by the return of patients to the SC treatment showing the direct relation of this novel decay Figure 2.

No grade 3 or above adverse events were identified. The most worrisome adverse event was an overnight upper gastrointestinal bleeding after PSE with no hemodynamic instability. This patient was kept overnight and underwent endoscopy that demonstrated gastric lacerations probably caused by forceful vomiting (Mallory–Weiss syndrome) with no need for any intervention. A CT was also performed showing, besides the embolized spleen, normal findings. This patient did not show a relevant decrease in the hemoglobin status and was discharged within 24 h. As for other adverse events, 12 patients (35%) referred low to moderate pain (three patients [9%] had severe pain), seven patients (21%) had low-grade fever, seven patients (21%) had nausea (two of which had vomiting). There were no significant changes in bilirubin: mean total bilirubin was 0.80 prior to and 0.59 after PSE.

Logistical and linear models did not show any association of number of cycles, estimated fraction of spleen necrosis by angiography, estimated fraction of spleen necrosis by CT, type of material, and size of particle with the percent of patients achieving platelet count >130 × 10⁹/L or with platelet count at week 2 (all P > 0.05).

The estimated fraction of spleen necrosis by angiography significantly correlated with the estimated fraction of spleen necrosis by CT (Beta = 0.85, P < 0.001, linear regression), with angiography slightly overestimating the infarction area (Fig. 3).

**Discussion**

In this study, we elected a platelet count of 130 × 10⁹/L as our primary endpoint since it is a safe value for the administration of SC. A total of 86% of the patients achieved platelets levels at that limit 2 weeks after PSE and, overall, it was reached by 94% of patients. These findings show how effective this approach can be which is also consistent with past studies [11, 12, 17]. Recomence of anti-cancer drugs, our secondary goal, occurred in all patients for whom SC was deemed necessary (in 31 out of 33 patients). Two patients did not return to SC, despite significant increase in the platelet count; the medical oncologist reached this decision after case review.

PSE is considered a safe procedure. Low-grade fever, mild pain, and nausea are common and interpreted as a postembolization syndrome [11, 15, 18, 19]. Even though severe complications, such as sepsis, portal vein thrombosis, overwhelming pulmonary infection and others, have been attributed to splenic embolization [2, 20], equivalent clinical worrisome conditions were not recognized in this study. One patient developed a single hematemesis episode with no serious consequences. Major complications after PSE usually arise from a large area of spleen embolization and are not necessarily associated with a more

![Figure 2](image1.png)

**Figure 2.** Platelets by week: Mean platelet count prior to partial splenic embolization (PSE) was 69 × 10⁹/L. Mean platelet count at weeks 1, 2, 3, and 4 post-PSE were, respectively, 141 × 10⁹/L, 188 × 10⁹/L, 154 × 10⁹/L, 122 × 10⁹/L. Platelets count new decrease at week 3 followed the return of patients to Systemic chemotherapy (SC) treatment.

![Figure 3](image2.png)

**Figure 3.** Estimated fraction of spleen necrosis by angiography significantly correlated with the estimated fraction of spleen necrosis by computed tomography.
efficient result [17, 21, 22]. In our study, most of the patients had a 50–70% infarction area with no major complications. In 60% of our cases, PSE was conducted as an outpatient procedure. Patients were kept overnight if they needed symptomatic treatment. This result is consistent with more recent publications in which overnight patient in-hospital monitoring was not the rule [12, 23].

SC treatments, which involve oxaliplatin, have been linked to the appearance of distinctive liver lesions, such as hepatic sinusoids blockade, sclerosis of the perisinusoidal space, and veno-occlusive disease, affecting the normal hepatic parenchyma and occasioning portal hypertension [14]. Increases in spleen size, platelets splenic sequestration, and development of thrombocytopenia are surrogates of this toxicity [10]. In our study, oxaliplatin-based SC regimens were identified in 29 out of 33 patients (88%) before PSE and this could be one of the main reasons for the PSE effectiveness detected in which all patients demonstrated a significant and prompt increase in platelet count. Bevacizumab would be an interesting option in the treatment arsenal for this subset of patients since it has survival benefit in the metastatic colorectal malignancy but also because of its potential protective role against oxaliplatin-mediated sinusoidal obstruction syndrome and splenomegaly as previously published [24]. Unfortunately, this monoclonal humanized antibody directed against vascular endothelial growth factor is not routinely offered as hepatic sinusoids blockade, sclerosis of the perisinusoidal space, and veno-occlusive disease, affecting the normal hepatic parenchyma and occasioning portal hypertension [14]. Increases in spleen size, platelets splenic sequestration, and development of thrombocytopenia are surrogates of this toxicity [10]. In our study, oxaliplatin-based SC treatments, which involve oxaliplatin, have been linked to the appearance of distinctive liver lesions, such as hepatic sinusoids blockade, sclerosis of the perisinusoidal space, and veno-occlusive disease, affecting the normal hepatic parenchyma and occasioning portal hypertension [14]. Increases in spleen size, platelets splenic sequestration, and development of thrombocytopenia are surrogates of this toxicity [10]. In our study, oxaliplatin-based SC treatments, which involve oxaliplatin, have been linked to the appearance of distinctive liver lesions, such as hepatic sinusoids blockade, sclerosis of the perisinusoidal space, and veno-occlusive disease, affecting the normal hepatic parenchyma and occasioning portal hypertension [14]. Increases in spleen size, platelets splenic sequestration, and development of thrombocytopenia are surrogates of this toxicity [10].

In conclusion, PSE appears secure and efficient in handling thrombocytopenia secondary to SC facilitating the continuation of the proposed oncological regimen. The substantial and rapid expansion in the thrombocytes numbers following partial splenic embolization suggests that aiming for a no more than 70% infarcted area may be sufficient to achieve success without the complications associated with more extensive parenchymal infarction. This finding, combined with the better safety profile of PSE, makes it an excellent therapy option in the management of CIT, enabling patients to resume systemic chemotherapy with minimal procedure-related morbidity.

Conflict of Interest

The authors of this work declare no conflicts of interest.

References

1. Castaneda-Zuniga, W. R., D. E. Hammerschmidt, R. Sanchez, and K. Amplatz. 1977. Nonsurgical splenectomy. AJR Am. J. Roentgenol. 129:805–811.
2. Gledhill, K., H. Singh, and G. Soares. 2007. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the English language literature. J. Vasc. Interv. Radiol. 18:463–481.
3. Ahuja, C., K. Farsad, and M. Chadha. 2015. An Overview of Splenic Embolization. AJR Am. J. Roentgenol. 205:720–725.
4. Elfeky, M. A., R. Paz-Fumagalli, A. M. Tiemeier, S. Pungpapong, D. M. Sella, and G. T. Frey, et al. 2015. Choice of partial splenic embolization technique in liver transplant recipients correlates with risk of infectious complications. Transplant Proc. 47:2932–2938.
5. Ekeh, A. P., S. Khalaf, S. Ilyas, S. Kauffman, M. Walusimbi, and M. C. McCarthy. 2013. Complications arising from splenic artery embolization: a review of an 11-year experience. Am. J. Surg. 205:250–254. discussion 254
6. Cai, M., W. Huang, C. Lin, Z. Li, J. Qian, and M. Huang, et al. 2016. Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors...
for platelet increment and risk factors for major complications. Eur. Radiol. 26:370–380.
7. Pålsson, B., M. Hallén, A. M. Forsberg, and A. Alwmark. 2003. Partial splenic embolization: long-term outcome. Langenbecks Arch. Surg. 387:421–426.
8. Hypersplenism, Peck-Radosavljevic M. 2001. Eur. J. Gastroenterol. Hepatol. 13:317–323.
9. Rios, R., B. Sangro, I. Herrero, J. Quiroga, and J. Prieto. 2005. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am. J. Gastroenterol. 100:1311–1316.
10. Overman, M. J., D. M. Maru, C. Charnsangavej, E. Loyer, H. Wang, and P. Pathak, et al. 2010. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J. Clin. Oncol. 28:2549–2555.
11. Kauffman, C. R., A. Mahvash, S. Kopetz, R. A. Wolff, J. Ensor, and M. J. Wallace. 2008. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 112:2283–2288.
12. Bhatia, S. S., S. Venkat, A. Echenique, C. Rocha-Lima, M. H. Doshi, and J. Salsamendi, et al. 2015. Proximal splenic artery embolization in chemotherapy-induced thrombocytopenia: a retrospective analysis of 13 patients. J. Vasc. Interv. Radiol. 26:1205–1211.
13. Perry, M. C., D. C. Doll, and C. E. Freter. 2012. Chemotherapy source book, 5th ed.. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.
14. Rubbia-Brandt, L., V. Audard, P. Sartoretti, C. Brezault, M. Le Charpentier, and B. Dousset, et al. 2004. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol. 15:460–466.
15. Madoff, D. C., A. Denys, M. J. Wallace, R. Murthy, S. Gupta, and E. P. Pillsbury, et al. 2005. Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S191–S211.
16. Petermann, A., P. Chabrot, L. Cassagnes, E. Dumousset, A. Alfidja, and C. Cageanu, et al. 2012. Hypersplenism due to portal hypertension: retrospective evaluation of 17 patients treated by splenic embolization. Diagn. Interv. Imaging 93:30–36.
17. Han, M. J., H. G. Zhao, K. Ren, D. C. Zhao, K. Xu, and X. T. Zhang. 1997. Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients. Cardiovasc. Intervent. Radiol. 20:125–127.
18. Gonsalves, C. F., E. P. Mitchell, and D. B. Brown. 2010. Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer. AJR Am. J. Roentgenol. 195:1241–1244.
19. Sibulesky, L., J. H. Nguyen, R. Paz-Fumagalli, C. B. Taner, and R. C. Dickson. 2009. Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C. World J. Gastroenterol. 15:5010–5013.
20. Zhu, K., X. Meng, J. Qian, M. Huang, Z. Li, and S. Guan, et al. 2009. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. Dig. Liver Dis. 41:411–416.
21. N’Kontchou, G., O. Seror, V. Bourcier, D. Mohand, Y. Ajavon, and L. Castera, et al. 2005. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur. J. Gastroenterol. Hepatol. 17:179–184.
22. Cai, M., K. Zhu, W. Huang, X. Meng, K. He, and B. Zhou, et al. 2013. Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up. J. Vasc. Interv. Radiol. 24:1808–1816.
23. He, X. H., W. T. Li, W. J. Peng, G. D. Li, S. P. Wang, and L. C. Xu. 2011. Total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism. World J. Gastroenterol. 17:2953–2957.
24. Imai, K., Y. Emi, K. I. Iyama, T. Beppu, Y. Ogata, and Y. Kakeji, et al. 2014. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur. J. Surg. Oncol. 40:559–566.
25. Jung, E. J., C. G. Ryu, G. Kim, S. R. Kim, H. S. Park, and Y. J. Kim, et al. 2012. Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res. 32:3357–3362.
26. Washington, K., K. L. Lane, and W. C. Meyers. 1993. Nodular regenerative hyperplasia in partial hepatectomy specimens. Am. J. Surg. Pathol. 17:1151–1158.